Authors
Matthias Tenbusch, Sofie Schumacher, Emanuel Vogel, Alina Priller, Jürgen Held, Philipp Steininger, Stephanie Beileke, Pascal Irrgang, Ronja Brockhoff, Jon Salmanton-García, Kathrin Tinnefeld, Hrvoje Mijocevic, Kilian Schober, Christian Bogdan, Sarah Yazici, Percy Knolle, Oliver A Cornely, Klaus Überla, Ulrike Protzer, Hedwig Roggendorf, Otto Zelger, Catharina Christa, Samuel Jeske, Sarah Heringer, Rayya Alsalameh, Jan Esse, Jochen Mattner, Monika Wytopil
Publication date
2021/9/1
Journal
The Lancet Infectious Diseases
Volume
21
Issue
9
Pages
1212-1213
Publisher
Elsevier
Description
The Oxford-AstraZeneca COVID-19 vaccine ChAdOx1 nCoV-19 is associated with a risk for vaccineinduced immune thrombosis with thrombocytopenia syndrome in the range of one to two cases per 100 000 vaccinations, with younger women showing the highest risk. 1, 2 Additional cases have been reported for the Johnson & Johnson adenoviral vector-based Ad26. CoV2. S COVID-19 vaccine. 3 Vaccine-induced antibodies against platelet factor 4 have been implicated in the pathogenesis. 1, 2 These antibodies might be amplified by booster vaccination with an adenoviral vector, which prompted recommendations to boost with an mRNA-based vaccine instead, although data on safety and efficacy of heterologous prime–boost regimens are sparse. 4 We quantified the vaccine-induced antibody response in vaccinees in Germany who received a heterologous COVID-19 vaccination scheme using ChAdOx1 nCoV …
Total citations
Scholar articles
M Tenbusch, S Schumacher, E Vogel, A Priller, J Held… - The Lancet Infectious Diseases, 2021
M Tenbusch, S Schumacher, E Vogel, A Priller, J Held…